Axsome Therapeutics Inc (AXSM) — 13F Holders Deep Dive (Q2 2026)

AXSM ranks #1149 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AXSM is a top-conviction position for Alethea Capital Management, LLC — at 65.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AXSM belongs to BlackRock, Inc., but the position matters far more to Alethea Capital Management, LLC, who has 65.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its AXSM position for two straight quarters, increasing it by $160.9M to reach $376.7M today.

Price T Rowe Associates Inc /md/ has trimmed its AXSM position for two straight quarters, cutting it by $118.4M while still holding $157.4M.

AXSM is up 3.5% today, and institutions have been net buyers of $2.4B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AXSM reported a net loss of $191.6M over the trailing twelve months.

• Not yet profitable — net loss of $191.6M over the trailing twelve months
• Revenue grew 56.9% year over year
• Net income improved year over year, from -$246.9M to -$191.6M
• Operating cash flow was negative, using $93.4M in cash
• Current ratio of 1.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 6.81x equity — a highly leveraged balance sheet worth noting